Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Kyung‐min Lee(University of Central Florida), Carlos L. Arteaga(The University of Texas Southwestern Medical Center)
Cited by 59
Related Papers
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
|Breast Cancer Research|2011|463
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
|Cancer Discovery|2021|241
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
|Nature Genetics|2015|166
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
|JAMA Oncology|2020|106
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
|Journal of Clinical Oncology|2019|82